《Table 1 Ongoing trials on lung cancer immunotherapy》

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《Immunotherapy–new perspective in lung cancer》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

1ClinicalTrials.gov registry number.NSCLC:Non-small cell lung cancer.

Durvalumab was compared to placebo in stage III NSCLC patients after unsuccessful chemoradiotherapy.The 24-mo OS rate was better in the immunotherapy group（66.3%vs 55.6%）.The median time to death or distant metastasis was 28.3 mo vs 16.2mo also better in the durvalumab group.The most frequent AE leading to the discontinuation of treatment was pneumonitis（4.8%in durvalumab group vs 2.6%in placebo group）.Death due to AEs occurred in durvalumab（4.4%）and placebo group（6.4%）[34].After that trial，the idea of immunotherapy for adjuvant setting was rekindled，and，nowadays，have been evaluated by an amount of current studies[35]（Table 1）.